menu
    • menu
    [{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Curis \/ Cantor Fitzgerald","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Undisclosed"},{"orgOrder":0,"company":"Curis","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Curis \/ Laidlaw & Company","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Laidlaw & Company"}]

    Find Clinical Drug Pipeline Developments & Deals for Emavusertib

    Menu

    Emavusertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Laidlaw & Company

                            Deal Size : $7.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

                            Details : Curis intends to use the net proceeds on research and development, including CA-4948 (emavusertib), an orally available, small molecule IRAK4 inhibitor.

                            Product Name : CA-4948

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 02, 2025

                            Lead Product(s) : Emavusertib,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Laidlaw & Company

                            Deal Size : $7.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Ibrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

                            Details : CA-4948 (emavusertib) is an IRAK4/FLT3/CLK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with Refractory Primary Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2023

                            Lead Product(s) : Emavusertib,Ibrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of Florida

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

                            Details : Under the terms of the agreement, Curis will supply emavusertib and Merck will supply pembrolizumab & bear the costs for clinical study of the novel combination of CA-4948 (emavusertib) and pembrolizumab (anti-PD1) in metastatic melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : Emavusertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of Florida

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Aurigene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

                            Details : CA-4948 (emavusertib) is a triple target inhibitor (IRAK4, FLT3 and CLK), which is investiated for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 06, 2023

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Aurigene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $15.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Curis Announces $15.1 Million Registered Direct Offering

                            Details : Curis intends to use the net proceeds from the offering on research and development of CA-4948 (emavusertib), an Oral, small molecule IRAK4 kinase inhibitor, being developed for the treatment of Leukemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 06, 2023

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cantor Fitzgerald

                            Deal Size : $15.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Aurigene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

                            Details : With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Aurigene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Stud...

                            Details : Emavusertib (CA-4948) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 30, 2022

                            Lead Product(s) : Emavusertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Aurigene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

                            Details : CA-4948 (emavusertib) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 18, 2022

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Aurigene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hema...

                            Details : CA-4948 (emavusertib), is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : Emavusertib,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Curis

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emavusertib,Ibrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting ...

                            Details : TakeAim Lymphoma data for the combination of CA-4948 (emavusertib) plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 04, 2022

                            Lead Product(s) : Emavusertib,Ibrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth